Physician profile
Clyde A Collins
NPI 1043465214
$1,585.74
in general payments reported to CMS, 2019-2025
28 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $64.37 · 2021: $15.35 · 2022: $400 · 2023: $197 · 2024: $386 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $348.37 | 2019-2024 | Entyvio, Eohilia |
| Abbvie INC. | $284.37 | 2019-2025 | |
| Janssen Biotech, INC. | $100.68 | 2022-2024 | Tremfya, Simponi, Stelara |
| Boston Scientific Corporation | $85.59 | 2019 | |
| Ironwood Pharmaceuticals, INC | $85.48 | 2022-2023 | Linzess |
| Amgen INC. | $71.77 | 2022-2023 | Amjevita, Avsola |
| Lilly USA, LLC | $68.22 | 2025 | Omvoh |
| Genzyme Corporation | $47.52 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $43.74 | 2024-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $43.64 | 2023 | |
| Laborie Medical Technologies Corp. | $36.40 | 2024 | Renovarp |
| Gilead Sciences, INC. | $34.89 | 2019-2022 | |
| Ucb, INC. | $30.88 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $29.50 | 2019-2022 | |
| Celltrion USA INC. | $29.33 | 2024 | Zymfentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.81 | 2022 | |
| Allergan, INC. | $24.98 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.35 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.94 | 2024 | Cyltezo |
| Madrigal Pharmaceuticals | $22.01 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $21.89 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.41 | 2022 | |
| Daiichi Sankyo INC. | $20.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.89 | 2024 | Trulance |
| Cumberland Pharmaceuticals, INC. | $13.68 | 2019 | |
| Pfizer INC. | $13.27 | 2023 | |
| Covidien LP | $12.64 | 2020 | |
| Phathom Pharmaceuticals, INC. | $6.65 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.